Product Pipeline Status Table
Our current approach is to search for opportunities where we can use our scientific expertise in the fields of protein purification, molecular biology, genomics and proteomics to create unique, competitive, and if possible, proprietary and/or patented products. We also focus on expanding into other uses for purified proteins, principally for diagnostic applications. An important factor in the development of diagnostics products is the general potential to proceed relatively quickly from product conception to saleable product as compared to human therapeutic products which are much more expensive to develop, often carry more safety and efficacy risks, take longer to get to market and face significantly more stringent regulatory requirements.
Products currently in our pipeline consist of product candidates in various stages of clinical and pre-clinical development. Our primary business strategy is to focus on products and technologies which we believe have attractive worldwide markets and relatively short time lines to generating revenue. Our appendicitis screen tests AppyScore and AppyScreen are examples of this focus. We also pursue technologies under “in-licensing” agreements with third parties such as universities, researchers or individuals; add value by advancing the stage of research and development on the technologies through proof of concept, and then will either “out-license” to “Large Pharma and / or Diagnostic” companies and/or continue with in-house development towards regulatory approval, product introduction and launch. Presently many if not all development products in our existing pipeline are under the regulatory jurisdiction of the FDA.
Following is a summary of our current key products and their development status:
| Product | Use | Stage | Revenue | FDA Approval |
| Diagnostic Products: | ||||
| AppyScore™ | ELISA ER Hospital Test | Development | Pre | Underway |
| AppyScreen™ | Physicians Office/Urgent Care Test | Development | Pre | Pre |
| SurBred™ | Bovine pregnancy status | Development | Pre | N/A |
| Recombinant Analog Drugs: | ||||
| BoviPure LH™ | Pregnancy enhancement/maintenance | Development | Pre | Underway |
| BoviPure FSH™ | Bovine super ovulation | Development | Pre | Underway |
| EquiPure LH™ | Induce equine ovulation | Development | Pre | On Hold |
| EquiPure FSH™ | Equine super ovulation | Development | Pre | Pre |
| Antigen Products | Test kit controls | Production | Recurring | N/A |
Table—Overview of current pipeline.
